Biotech & Pharma

STAT+: At AACR, more strong results for Revolution Medicine's KRAS drug, plus assurance from NCI's director

alinemati1983-69874 days ago

25 sec read2 views0 listens

Revolution Medicines' experimental KRAS drug, daraxonrasib, showed strong results in second-line pancreatic cancer treatment, doubling median survival times compared to chemotherapy. This breakthrough is crucial for developers and tech professionals as it opens new avenues for targeted cancer therapies and may accelerate the development of similar precision medicines. Watch for further clinical trial outcomes and potential regulatory approvals.

Read the full article at STAT Pharma

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

alinemati1983-6987Written by alinemati1983-6987

View all posts

Biotech & PharmaFeb 2627 sec read

STAT+: FDA Commissioner Marty Makary defends rare disease drug rejections, Vinay Prasad

FDA Commissioner Marty Makary defended recent rejections of rare disease drugs and top FDA official Vinay Prasad against criticism, emphasizing the agency's commitment to rigorous standards despite pressure for approvals. This stance underscores the ...

Ali Nemati

Biotech & PharmaFeb 2529 sec read

Novo Nordisk teams with Langer-founded biotech for oral obesity drugs

Novo Nordisk is collaborating with a biotech company founded by MIT’s Robert Langer to develop oral biologics for treating obesity and diabetes, marking significant advancements in drug delivery methods. This partnership could revolutionize treatment...

Ali Nemati

Biotech & PharmaFeb 2527 sec read

GSK to buy pulmonary hypertension biotech 35Pharma for $950M

GlaxoSmithKline (GSK) acquired 35Pharma for $950 million to gain access to their pulmonary hypertension drug program, expanding GSK's therapeutic portfolio. This move is significant as it enhances GSK’s presence in specialized pharmaceutical markets ...

Ali Nemati

Biotech & PharmaMar 432 sec read

STAT+: Pharmalittle: We're reading about Moderna's $2.25 billion settlement, FDA warning letters, and more

Moderna settled a patent infringement lawsuit with Roivant for up to $2.25 billion, avoiding an upcoming jury trial and providing financial relief for Roivant; Virginia lawmakers are proposing an affordability board that will use Medicare as a benchm...

Ali Nemati

Biotech & PharmaFeb 2432 sec read

STAT+: Drugmakers lay out their legal arguments against Trump's drug pricing experiments

Pharmaceutical and biotech industries are opposing Trump administration's proposed Medicare pilot programs aimed at lowering drug prices by aligning them with international rates, signaling potential future legal challenges once the proposals are fin...

Ali Nemati

STAT+: At AACR, more strong results for Revolution Medicine's KRAS drug, plus assurance from NCI's director

Related Articles

STAT+: FDA Commissioner Marty Makary defends rare disease drug rejections, Vinay Prasad

Novo Nordisk teams with Langer-founded biotech for oral obesity drugs

GSK to buy pulmonary hypertension biotech 35Pharma for $950M

STAT+: Pharmalittle: We're reading about Moderna's $2.25 billion settlement, FDA warning letters, and more

STAT+: Drugmakers lay out their legal arguments against Trump's drug pricing experiments